Skip to main content
Sign In
 

PhD in Pharmaceutical Sciences, Pharmaceutical Outcomes Research Track

Current Students




Kimberly Deininger was born and raised in Cleveland, Ohio. She graduated from Case Western Reserve University with a BS in Biology in 2006. She then moved to Colorado and earned an MPH in Epidemiology from the Colorado School of Public Health in 2015. She began working with Dr. Christina Aquilante during her master’s program, studying pharmacogenomics in cardiac transplant patients. She joined the POR program in 2016 to advance her research skills and pursue her goal of improving upon medications. She feels that the faculty in this program are unparalleled, as they provide diverse research interests, opportunities, and expertise in all areas of pharmaceutical outcomes research. She continues to conduct research in Dr. Aquilante’s lab, focusing on the clinical utility of pharmacogenomics in solid organ transplantation. In her free time, Kimberly enjoys hiking in the mountains, watching live music, and traveling. LinkedIn: https​://www.linkedin.com/in/kmdeininger/​


Katia Hannah is a Washington State native. She graduated from Washington State University with a BS in Zoology in 2010. She then moved to Colorado to attend Colorado School of Public health, completing both the Certificate and Masters in Public Health programs with a focus in epidemiology. During the master's program, she worked with Dr. Rob Valuck and Dr. Heather Anderson on her capstone project studying the association between anticholinergic toxicity and adverse health outcomes using measures of toxicity generated by three anticholinergic toxicity scales. She joined the CePOR program in fall 2016 and is currently conducting health outcomes research focusing on Epinephrine Auto-Injectors with Dr. Robert Brett McQueen.


Chong Kim (CK) was born in East Lansing Michigan and spent most of his time in Michigan until he graduated in 2009 with a BS in Biochemistry from the Michigan State University. He went on to receive his MPH in Health Policy and Management from the Columbia University Mailman School of Public Health in 2013. He worked as a junior analyst in Korea, identifying cost-effective therapies for ovarian cancer and Cushing's disease, such that formulary decisions could be updated. CK started the PhD program in Pharmaceutical Outcomes Research in fall 2015 and has been interested in utilizing machine learning and statistical models to determine the impact of short-acting beta-agonist on clinical and economic outcomes of asthma patients. CK has a website featuring some of the research he's doing. 




Sue Kwon is from Seoul, South Korea, and majored in Neuroscience at Pomona College. The goal of her current project is to evaluate the cost-effectiveness of multiple sclerosis (MS) disease modifying therapies (DMT) using a claims database. She hopes to advocate for health equality and support underserved communities, LGBTQ+ communities, and immigrant communities through outcomes research. Thanks to the wonderful mentorship that the CEPOR faculty offers, Sue has been able to establish a balance between research and academics her first year. In her free time, she likes to travel, cook, and spend time with friends. Pronouns: She, her, hers, Github: https://github.com/shyunk, Linkedin: https://www.linkedin.com/in/suehkwon​.




Nicholas Mendola: 



Vanessa Paul Patterson grew up in Kansas City before moving to New Orleans in 2006. She graduated from Tulane University with a BSPH in Environmental Health Sciences in 2010 and stayed on at Tulane University School of Public Health and Tropical Medicine to complete her MPH with a dual concentration in Epidemiology and Maternal and Child Health in 2012. Vanessa went on to work as an applied epidemiologist for government public health agencies for six years. Her work covered a range of topics, including environmental health, occupational health and injury, chronic diseases, and infectious diseases. Vanessa joined the Pharmaceutical Outcomes Research track in the fall of 2018. She is currently working with Dr. Melanie Whittington in support of the Data Science to Patient Value (D2V) NavLab. 

 

Why CU's Pharmaceutical Outcomes Research PhD track?

Chong Kim: There were several factors that ultimately led me to choose POR training program. The biggest factor was the research output from alumni. Although individual capacity may determine the amount of research that may be done, I felt that at least everyone had enough exposure to opportunities to contribute to various projects that the faculty were a part of. Another factor was the prospects for a future career. Some of the alumni graduated to take the academic route, some took on the industry route. What allowed me to be at ease of mind was the fact that none of them had difficulty in job searching and were doing quite well due to the opportunities (research and networking) they had during their stay in the program. I’ve been involved in several projects throughout my first and second semester and I know I’ve definitely made the best choice in coming to this program based on just that.
​​​​​​​​​​​​​​​​​​​​​​​​​​​